Group items tagged

As Ayurveda turns into more and more popular in North the us, it seems inevitable that many will become privy to some of its more essential remedies. And amongst those diverse remedies the herb Ashwagandha has taken on a unique prominence, such that many people are now using it. permit's explore Ashwagandha: its diverse attributes, properties, Ashwagandha blessings and uses, Ashwagandha dosage; or even some of its potential contraindications, to properly guide its utilization.

Indian food consists of a large variety of traditional and regional cuisines native to the Indian sub-regions. Given the range of broad diversity in climate, soil type, culture, occupations, and ethnic groups, these cuisines vary substantially from each other and what adds to their uniqueness are the locally available spices and herbs. It comes as a no brainer that Indian cuisine is one of the most popular cuisines across the world. , but people in North America, Europe, Australia, and Africa can not have enough of it.

According to the latest study by WHO, fourteen of the world's 15 most polluted cities are in India. Amongst the 4300 polluted places Kanpur tops the list as the most polluted place in India with the least air quality index.

Natural Dental Partners is the top rated Holistic Phoenix Dentist Office. Dr. Mahn is a nationally recognized natural and biological dentist who recently relocated to North Phoenix. Natural Dental Partners patients receive a unique approach to dental care that combines a holistic and biological philosophy with state of the art technology to help patients achieve healthy results for their mouth and bodies.

North America leads the global heart failure drugs market in 2018 followed by Europe. The US dominates the market owing to the presence of a majority of the heart failure drugs manufacturers in the region. However, the fastest growth rate is anticipated to be in the APAC region due to the presence of large heart failure patient population and availability of wide range of drugs. Most of the revenue is generated from the leading players in the market with dominant sales from Novartis AG, GlaxoSmithKline PLC, AstraZeneca PLC, Bayer AG, and Pfizer Inc.

Here we bring some exciting news for McDonald's lovers in North India! The McDonald's connoisseurs have faced a lot of disappointment in recent times when all the outlets were shut down. But now no more disappointment! We got some silver lining with a pleasant twiston the dark clouds. McDonald's islaunchingMcCafé in Delhi, to add to the delight of 'Mc D fans'!

Existing Covid-19 inoculations will struggle against the fast-spreading Omicron variant, the head of vaccine manufacturer Moderna warned on Tuesday (November 30), as countries ramp up vaccination programmes and impose further restrictions in an effort to curb growing concern. First reported to the World Health Organization in South Africa less than a week ago, the new strain has rapidly spread from Africa to the Pacific, and from Europe to North America as dozens of countries have announced travel restrictions. While no deaths have yet been reported from Omicron, and it could take weeks to know how infectious and how resistant the strain may prove to vaccines, its emergence underscores how besieged the world remains by Covid-19, nearly two years after the first cases were recorded. Stephane Bancel, the head of US vaccine manufacturer Moderna, told the Financial Times in an interview published today that data would be available on the effectiveness of vaccines in the two weeks' time, but that scientists were pessimistic.

The parent company of Boots, Britain's largest pharmacy-led health and beauty chain, is reportedly considering putting its UK pharmacies up for sale next year for an estimated £10 billion. Walgreen Boots Alliance (WBA), the US health group that owns a stake in Boots UK since 2012, is lining up Goldman Sachs to explore a potential sale next year, as reported by Sky News. When contacted by Pharmacy Business, WBA said that it would not comment on "market speculation", noting that "Boots is an important part of the Group." The company, however, acknowledged that "it is accurate that WBA announced a renewed set of priorities and strategic direction for the Group in October, which includes a more pointed focus on North America and on healthcare."

Balmedie Pharmacy based in Aberdeenshire, Scotland has been purchased by local expanding multiple operator JMF Healthcare. Balmedie Pharmacy is a well-performing community pharmacy that dispenses an average of 5,255 items per month. It lies completely unopposed in the large Aberdeenshire village of Balmedie, which is circa eight miles north of Aberdeen City Centre. The pharmacy has been owned by Brian Arris since 2004 and was recently brought to market to allow him to pursue other pharmacy business opportunities. Following a confidential sales process with Christie & Co, JMF Healthcare to benefit from new housing developments in this area of Aberdeenshire such as 300 new homes planned in Balmedie, approved plans for up to 500 new homes in Trump Menie Estate, and 284 new homes planned in Blackdog Village. Brian Arris, previous owner of Balmedie Pharmacy, comments, "I'm sad to see the business go as the excellent staff have helped grow the pharmacy from scratch since 2004 and we've all put our hearts and souls into providing good pharmaceutical care for the village and surrounding area. I'm confident everyone is left in safe hands with John at the helm now."

National Pharmacy Association (NPA) has appointed Nick Kaye as its new chair on Monday (24 April). He has taken over the chairmanship from Andrew Lane, who stood down last month after serving his maximum term. Nick, who part-owns Hendra Pharmacy in Cornwall will serve for two years as NPA chair, after being elected unopposed at the first meeting of the new NPA board. Jay Badenhorst, Managing Director and Superintendent Pharmacist for Whitworth Chemists in the North East of England, is now vice-chair. Michael Guerin, the Managing Director and Superintendent Pharmacist of the Medicare group in Northern Ireland, continues as Treasurer. Nick Kaye said: "As a third generation community pharmacist, I feel very privileged to serve the sector that I love so dearly in this way. "Andrew will be a hard act to follow. But I can promise my unwavering commitment to independent community pharmacy, with Jay and Michael's 's support, plus that of board colleagues and our dedicated executive team.

Capitalising on strong demand for its obesity therapies, Novo Nordisk's growing appetite for deals has fuelled a bet on a U.S. gene-editing company called Life Edit Therapeutics. The Danish drugmaker's collaboration with Durham, North Carolina-based Life Edit Therapeutics - owned by ElevateBio, a cell and gene therapy company in Waltham - is focused on up to seven programs for rare genetic disorders as well as cardiometabolic diseases. At the heart of the tie-up is Life Edit's technology, called base editing, which is designed to make precise changes to the human genome by tweaking one base - or letter - into a different one without affecting other letters. Single-letter mistakes, called point mutations, can give rise to genetic diseases.

As we transition in England through yet another NHS organisational change, I ask myself what does this mean for community pharmacy? I would like to think that this change will bring about opportunity and a chance for community pharmacy to showcase and continue the excellent work that was carried out during the height of the pandemic and is still ongoing today. I hope that it allows community pharmacy to be regarded as part of the NHS rather than sitting on the side lines. This change has to lead to better funding for community pharmacy, without sufficient funding we will see more pharmacies close. We are hearing a lot about winter pressures but this year it feels like all year round pressure. What I have seen, whilst the NHS is under such pressure, is North East London (NEL) CCG transitioning to an integrated care board (ICB) almost seamlessly. I have seen people transitioning into new roles, whilst working hard to ensure that all plates are still spinning, which at the moment is no mean feat. I spent a day out recently visiting pharmacies with the chief medical officer of NHS NEL, Dr Paul Gilluley. The visits were positive, we felt listened to and understood. The feedback was great, it was recognised that community pharmacy is often the informal front door to the NHS and that we have so much to offer in terms of ill health prevention. Community pharmacy can offer a total solution as long as we have the tools to do so, which can save so much time and money. An example is the GP CPCS service, which has launched well across NEL.

Prime minister Rishi Sunak appointed Conservative MP for North East Cambridgeshire Steve Barclay as secretary of state for health and social care on 25 October 2022. He previously held the same role between 5 July and 6 September - after Sajid Javid resigned as health secretary. As head of the Department of Health and Social Care (DHSC) his responsibilities will include "overall financial control and oversight of NHS delivery and performance" as well as "oversight of social care policy". Mr Barclay was succeeded by Thérèse Coffey, who thanked her "great ministerial team" at the DHSC in a Tweet, before taking up her new responsibility as environment secretary in the new cabinet. As head of the Department of Health and Social Care (DHSC) his responsibilities will include "overall financial control and oversight of NHS delivery and performance" as well as "oversight of social care policy". Mr Barclay was succeeded by Thérèse Coffey, who thanked her "great ministerial team" at the DHSC in a Tweet, before taking up her new responsibility as environment secretary in the new cabinet.

Sun Pharma has announced that it will acquire all outstanding shares of Concert Pharmaceuticals through a tender offer for an upfront payment of $8.00 per share of common stock in cash, or $576 million in equity value. The upfront payment of $8.00 per share of common stock in cash represents a premium of approximately 33% to Concert's 30-day volume weighted average price as of January 18, 2023, the last trading day prior to today's announcement. Concert is a late-stage biotechnology company pioneering the use of deuterium in medicinal chemistry. Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib - an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease - which is in late-stage development. It has completed the evaluation of the efficacy and safety of deuruxolitinib in adult patients with moderate to severe Alopecia Areata in its THRIVE-AA Phase 3 clinical program and two open label, long-term extension studies are ongoing in North America and Europe. Sun Pharma's immediate focus would be to follow Concert's plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of 2023.

In a mutual agreement with the STADA board, Roger Scarlett-Smith has stepped down from his role as head of UK. The company has assigned the responsibility of UK operation to Rudolf Bär with current responsibilities as cluster head for Mid-Sized European Markets. Scarlett-Smith joined STADA in October 2018 to lead the UK operation upon the retirement of Dieno George. Prior to this, he had enjoyed an illustrious career in the Consumer Healthcare sector, largely with GlaxoSmithKline, for which he held positions including as President North America, President EMEA and Head of Global Categories. Under his leadership, the STADA UK business has grown sales by 50 per cent and profitability has more than doubled. He has reshaped the business to improve efficiency. There has been a marked acceleration of product innovation including key line extensions to the Zoflora disinfectant range as well as the introduction of a salmeterol and fluticasone inhaler in the Rx respiratory sector. Meanwhile, T+R has developed a fine reputation regionally, being voted number 1 regional company last year and winning many national industry awards.

Dr Thérèse Coffey, the MP for Suffolk Coastal, has been appointed as health secretary - the fourth person to get the job after Jeremy Hunt, Matt Hancock, Sajid Javid and Steve Barclay in the past five years. She replaces Steve Barclay who held the job for just two months between July and September. Having first been elected in 2010 and subsequently re-elected in 2015, 2017 and 2019, Dr Coffey has served as secretary of state for the Department of Work and Pensions. Previous to that she served as environment minister, deputy leader of the House, government whip and parliamentary private secretary. As an MP she has campaigned on improving NHS experience for patients. Dr Coffey grew up in the North West and has a PhD in Chemistry and a chartered management accountant qualification.

Pharmanovia, the lifecycle management company has signed a licence and supply agreement with Aquestive Therapeutics for its patented diazepam buccal film formulation across the EU, UK, Switzerland, and Norway, as well as countries in the Middle East and North Africa (MENA)- up to 48 markets in total. Aquestive Therapeutics has been granted tentative approval by the US Food and Drug Administration (FDA), for its diazepam buccal film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older. Pharmanovia will be responsible for seeking appropriate regulatory approval across EU and MENA. Pharmanovia CEO, James Burt commented: "Pharmanovia and Aquestive are aligned in our mission to find new and innovative ways to enhance and revitalise iconic medicines. We have extensive experience with diazepam through the Valium brand and, together with Aquestive's unique PharmFilm technology, we're intending to bring a novel alternative diazepam delivery option to caregivers and patients at a time of critical need."

Bestway operates approximately 750 pharmacies nationwide in the UK under the Well brand. In April 2023, it completed its acquisition of Lexon, which operates 46 pharmacies in the UK under the Knights Pharmacy brand, and Asurex, a wholesale perfume supplier. On 26th May 2023, CMA announced the launch of its merger inquiry. A fast-track Phase 1 investigation found that the merger could lead to a significant lessening of competition between retail pharmacies in 12 local areas located in Liverpool and North East England. The merging businesses conceded that the deal raises competition concerns in these areas and have submitted proposals to sell pharmacies within these areas to restore the competition that would otherwise be lost as a result of the deal. Colin Raftery, CMA Senior Director of Mergers, said: "Pharmacies are essential public health services, and it's vital that the loss of competition brought about by a deal like this shouldn't leave people with reduced choice or worse services when they need medical support. The CMA will now carefully consider whether the remedy put forward by Bestway will address its concerns and ensure that customers in the affected areas continue to have access to good quality chemists.

The Competition and Markets Authority (CMA) has announced on Tuesday (20 June) that it may consider undertakings offered by Bestway Panacea Holdings, a parent company of Well Pharmacy, which involves divesting seven pharmacy stores under the merger deal with Lexon UK. The Authority said: "CMA considers that there are reasonable grounds for believing that the undertakings offered by Bestway, or a modified version of them, might be accepted by the CMA under the Enterprise Act 2002." Last week, the Authority had announced that the merger of Bestway, and independent pharmacy owner Lexon UK could "lessen the competition between retail pharmacies" in England. On 26th May 2023, CMA announced the launch of its merger inquiry. A fast-track Phase 1 investigation found that the merger could lead to a significant lessening of competition between retail pharmacies in 12 local areas located in Liverpool and North East England. The merging businesses conceded that the deal raises competition concerns in these areas and have submitted proposals to sell pharmacies within these areas to restore the competition that would otherwise be lost as a result of the deal.

Stone Pharmacy in Barnsley, South Yorkshire has been sold to existing operator, Livesey Healthcare, which owns another pharmacy in East Lancashire for an undisclosed price. Stone Pharmacy is a well-established, 100-hour community pharmacy that is run under full management with a locum Pharmacist, and dispenses an average of 22,000 items per month. The business adjoins Garland House surgery in the South Yorkshire village of Darfield, which is circa six miles east of Barnsley and circa 14 miles north of Sheffield. The pharmacy has been owned by experienced operators, Khuram Akhtar and Mohammed Ali, trading as MEDS2U Ltd, for the last seven years, and was recently brought to market to allow the pair to pursue new ventures both in and out of community pharmacy. Khuram Akhtar, former owner of Stone Pharmacy, commented: "The business at Stone Pharmacy has been a fantastic enterprise for many years for us, with limited competition and a position central to the local community we have always enjoyed the support of the nearby population and are pleased that it is now in the hands of experienced operators who can build on that foundation with the expansion of new services.